Feline Hypersomatotropism: IGF-1 and Treatment

Bottom line

Feline hypersomatotropism can be present without stereotypical acromegalic features or even without diabetes. [1] Screen with IGF-1 interpreted alongside diabetic treatment history, then use pituitary imaging and a referral discussion to plan disease-directed care. Normal imaging does not exclude a small functional lesion. [2]

Do not require the classic face or extreme insulin resistance

Hypersomatotropism describes excessive growth hormone secretion; acromegaly describes its physical consequences. Some cats have marked insulin resistance without obvious somatic changes, while others have physical or cardiac changes without diabetes. [1]

Record weight trajectory, appetite, physical changes, neurological findings, and the quality of glycemic control. Review insulin administration, glucose monitoring, medication exposure, and concurrent disease before assigning poor control to a pituitary cause.

The feline plantigrade-stance workup covers localization of weakness and competing metabolic or neurological causes. The posture is not an endocrine diagnosis.

Interpret IGF-1 with timing and assay context

IGF-1 is a practical surrogate for growth hormone because it is more stable and less affected by pulsatile secretion. Equivocal results warrant interpretation with the clinical presentation and the laboratory's assay. Insulin deficiency can lower IGF-1 early in diabetes. [1]

The 2025 iCatCare guideline notes that measurement after 6–8 weeks of diabetes treatment may be more reliable. It recommends reassessment of grey-zone results and recognizes that microadenoma or hyperplasia may escape CT or MRI detection. [2]

Preserve the exact assay, units, reference interval, treatment timeline, and reason for retesting. Avoid presenting a threshold derived from one assay or diabetic population as universally diagnostic in every cat.

Choose treatment goals before choosing a modality

Discuss biochemical disease control, diabetic control, pituitary mass effects, quality of life, cost, availability, and caregiver capacity separately. Better glucose control does not answer every question about growth hormone excess or the mass itself.

The guideline lists hypophysectomy, radiotherapy, pasireotide, and cabergoline among treatment approaches. Radiotherapy may reduce tumor size and neurological effects, but IGF-1 elevation can persist and multiple anesthetics may be needed. [2]

Arrange referral early enough that the caregiver can compare realistic local options. Obtain the treating center's expected monitoring and aftercare requirements rather than offering a generic success percentage.

Hypophysectomy includes substantial aftercare

In a retrospective surgical cohort, diabetic remission occurred in some cats, but early postoperative deaths, hypoglycemia, electrolyte disturbances, and transient congestive heart failure also occurred. Long-term hormone replacement was required. [3]

The reported remission proportion changes when the denominator is all operated cats versus postoperative survivors. [3] Use the appropriate denominator in counseling, and do not treat a retrospective referral cohort as a randomized comparison against medical therapy.

Before surgery, establish who will adjust diabetic treatment, monitor glucose and electrolytes, manage replacement therapy, and respond to neurological or fluid-balance changes. A plan to remove the source of excess hormone also needs a plan for the endocrine consequences of surgery.

Medical options have uneven evidence

A prospective nonblinded cabergoline pilot did not improve diabetic control, normalize IGF-1, or improve measured quality of life in its cohort. [4] This limits confidence in a predictable response; it does not establish that every individual cat will fail treatment.

If extra-label medical treatment is selected, document the intended outcome and the point for reconsidering it. Separate glucose response, biochemical response, adverse effects, and evidence of mass progression.

The velagliflozin evidence reference addresses a separate glycemic-treatment decision and its safety constraints. Recognizing hypersomatotropism does not automatically make a cat suitable for an oral diabetes drug.

Reassessment must follow more than insulin dose

Keep a longitudinal record of clinical status, glucose data, weight, functional change, IGF-1 results when indicated, and the chosen disease-directed treatment. Reopen the plan when the cat develops neurological changes, apparent treatment failure, or a mismatch between glycemic and systemic response.

Frequently Asked Questions

Does a normal-looking face exclude hypersomatotropism?

No. Cats can have excess growth hormone without obvious acromegalic physical changes. [1]

Must a cat have diabetes to have hypersomatotropism?

No. Diabetes may be absent in cats whose physical or cardiac changes predominate. [1]

Why can early IGF-1 testing be misleading?

Insulin deficiency can lower IGF-1 early in diabetes, so results require treatment-history context. [1]

What timing does the diabetes guideline suggest for a more reliable IGF-1 result?

The 2025 iCatCare guideline notes that testing after 6–8 weeks of diabetes treatment may be more reliable. [2]

Does normal pituitary imaging exclude disease?

No. Microadenoma or hyperplasia may not be detected by CT or MRI. [2]

Is hypophysectomy free of ongoing endocrine care?

No. The surgical cohort required long-term hormone replacement and documented important postoperative complications. [3]

Is cabergoline reliably effective in every affected cat?

No. The prospective pilot found no improvement in diabetic control, IGF-1 normalization, or measured quality of life in its cohort. [4]